News
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, supported by the Russian ...
13.07.2020
RDIF and ChemRar have produced the first 100,000 courses of Avifavir
In June Avifavir was delivered across Russia’s ...
02.07.2020
Moscow, June 11, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar ...
11.06.2020
Moscow, June 8, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group ...
08.06.2020
Avifavir is one of the two registered COVID-19 drugs in the world
Avifavir is the first drug registered in Russia ...
03.06.2020
Avifavir is the first direct-acting antiviral drug registered in Russia that has proven effective against COVID-19 in ...
01.06.2020
Median elimination of the virus in four days compared to nine days with standard therapy, according to the study ...
22.05.2020
Moscow, May 13, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group ...
14.05.2020
Russia is set to test the antiviral drug Favipiravir as a treatment for COVID-19 following "excellent results" in ...
07.04.2020
The drug has been used successfully in China to cure coronavirus patients
Moscow, March 26, 2020 – The Supervisory ...
26.03.2020
Avineuro Project from ChemRar Research Institute has finished the multicenter, randomized, double-blind, ...
27.11.2019
BIOTECHMED 2019 Forum that involved representatives of ChemRar Group and international accelerator biobridge-2019, ...
27.11.2019